LLY241115P460000
- 0.00
- 0.000.00%
Eli Lilly and Co Newsroom
Wolfe Research Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,000
Daiwa Adjusts Price Target on Eli Lilly & Co. to $900 From $940, Maintains Outperform Rating
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $975
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,029
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $975
Deutsche Bank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,015
Eli Lilly Analyst Ratings
Redburn Atlantic Adjusts Price Target on Eli Lilly to $700 From $640, Maintains Neutral Rating
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $994
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $970 to $1,146
Barclays Maintains Overweight on Eli Lilly, Lowers Price Target to $975
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $975 to $1,100
Eli Lilly Is Maintained at Buy by B of A Securities
Eli Lilly Analyst Ratings
Jefferies Adjusts Price Target on Eli Lilly to $994 From $1,113, Maintains Buy Rating
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Eli Lilly Analyst Ratings
Citigroup Maintains Buy on Eli Lilly, Raises Price Target to $1250
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,250